RDT Products
Rare Disease Therapeutics, Inc., (RDT) is currently developing Orphan products, acquiring Orphan products through strategic alliances, and distributing Orphan products through third-party contractors with facilities and logistics expertise to provide distribution throughout the Americas. RDT works closely with the FDA’s Office of Orphan Product Development, National Organization for Rare Disorders (NORD), the National Institutes of Health, large international pharmaceutical companies, and patient advocacy groups to identify the unmet needs of patients with rare diseases and potential products to meet these needs.
Anavip® (www.anavip-us.com)
ANAVIP® [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation. It contains venom-specific antigen binding F(ab’)2 fragments derived from equine hyperimmune plasma. These fragments bind to venom thereby preventing or reversing the local and systemic effects of rattlesnake envenomation.
Rattlesnake venoms may contain a broad variety of toxins, including neurotoxins, hematoxins, myotoxins and cytotoxins. Hemorrhagins commonly found rattlesnake venoms promote capillary leak, proteases, lipases, hyaluronidase, thrombin-like enzymes that promote defibrination, and platelet–aggregating factors.
Clinical consequences of rattlesnake envenomation included local and systemic injury, both of which may progress for hours or days. Local injury commonly involves edema, erythema, tenderness, ecchymosis, and hemorrhagic bulla formation. Injury always begins as a small region near the fang entry site, but rapid contiguous and lymphatic spread may result in the involvement of an entire limb within a few hours of envenomation. Systemic consequences of crotaline envenomation include shock, coagulopathy, and occasionally neurotoxicity. ANAVIP reduces the risk of recurring symptoms of a rattlesnake bite.
Anavip® [Crotalidae Immune F(ab’)2 (Equine)] is distributed in the US by RDT (Rare Disease Therapeutics, Inc.), a US based company. To order, please call 866-830-7350.
* Please see full prescribing information for a complete discussion of indications and usage, contraindications, warnings, precautions, adverse reactions, and overdosage.
Anascorp® (www.anascorp-us.com)
Anascorp® [Centruroides (Scorpion) Immune F(ab’)2 (Equine) Injection], a Centruroides immune F(ab’)2 is the first of a series of antivenoms in the Rare Disease Therapeutics, Inc., pipeline. Anascorp®, an F(ab’)2 antibody, is FDA approved for the treatment of scorpion envenomation from the Centruroides scorpions. Centruroides sculpturatus is the only scorpion species with vertebrate neurotoxins whose natural range includes the United States.
It is found in southeastern California, Arizona, Nevada, southern Utah, and southwestern New Mexico. It is also found throughout the Baja California Peninsula and western Sonora, Ensenada, B.C in México. A typical “bark” or “crevice” scorpion, C. sculpturatus is commonly encountered under rocks, logs, the bark of trees, and other surface objects.
Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from the trivial to life threatening. Severe envenomation, more common in small children, may involve neuromotor hyperactivity, pulmonary edema, and ventilatory compromise occasionally resulting in death.
Anascorp® Centroides (Scorpion) Immune F(ab’)2 (Equine) Injection is distributed in the US by RDT (Rare Disease Therapeutics, Inc.), a US based company. To order, please call 866-830-7437.
* Please see full prescribing information for a complete discussion of indications and usage, contraindications, warnings, precautions, adverse reactions, and overdosage.
Purixan® (www.purixan-us.com)
Purixan® (mercaptopurine) oral suspension, is a liquid version of an existing tablet-form used for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen. ALL is the most common childhood cancer.
It was developed to meet a need for greater dosing accuracy and improved palatability for children, and has been designated an Orphan Drug status by the FDA as it is indicated for the treatment of rare diseases or conditions.
Mercaptopurine has been available as a treatment for ALL for many years in a 50 mg tablet form. Healthcare professionals often had to split the 50 mg tablet form to provide children with the desired dose, the raspberry-flavored Purixan® liquid enables the measurement of precise doses that can easily be administered to pediatric and adult patients.
Purixan® (mercaptopurine) oral suspension is available in amber glass multiple-dose bottles containing 2000 mg/100 mL (20 mg/mL). Each bottle is equipped with with a child resistant closure.
Purixan® (mercaptopurine) oral suspension is distributed in the US by RDT (Rare Disease Therapeutics, Inc.), a US based company. To order, please call 888-470-0904.
* Please see full prescribing information for a complete discussion of indications and usage, contraindications, warnings, precautions, adverse reactions, and overdosage.